1. Home
  2. KALV vs GDRX Comparison

KALV vs GDRX Comparison

Compare KALV & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

N/A

Current Price

$15.64

Market Cap

757.7M

Sector

Health Care

ML Signal

N/A

Logo GoodRx Holdings Inc.

GDRX

GoodRx Holdings Inc.

N/A

Current Price

$2.01

Market Cap

868.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
KALV
GDRX
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
868.9M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
KALV
GDRX
Price
$15.64
$2.01
Analyst Decision
Strong Buy
Buy
Analyst Count
5
10
Target Price
$30.00
$4.78
AVG Volume (30 Days)
564.9K
3.2M
Earning Date
04-13-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
125.00
EPS
N/A
0.09
Revenue
$50,000,000.00
$796,853,000.00
Revenue This Year
N/A
$2.35
Revenue Next Year
$108.37
$2.53
P/E Ratio
N/A
$35.00
Revenue Growth
495.66
0.57
52 Week Low
$9.83
$2.10
52 Week High
$19.00
$5.61

Technical Indicators

Market Signals
Indicator
KALV
GDRX
Relative Strength Index (RSI) 53.36 37.08
Support Level $14.45 N/A
Resistance Level $16.33 $2.87
Average True Range (ATR) 0.69 0.16
MACD 0.07 0.01
Stochastic Oscillator 80.05 13.17

Price Performance

Historical Comparison
KALV
GDRX

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About GDRX GoodRx Holdings Inc.

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Share on Social Networks: